Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $30
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and lowers the price target from $34 to $30.
Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and lowers the price target from $34 to $30.